Liminatus Pharma, Inc. Class A Common Stock (LIMN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Liminatus Pharma, Inc. Class A Common Stock (LIMN) has a cash flow conversion efficiency ratio of 15.199x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.02 Million) by net assets ($-132.60K). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see LIMN market cap for the company's overall valuation and market capitalisation.
Liminatus Pharma, Inc. Class A Common Stock - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how Liminatus Pharma, Inc. Class A Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Liminatus Pharma, Inc. Class A Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Liminatus Pharma, Inc. Class A Common Stock ranked by their cash flow conversion efficiency. Explore cash flow quality index of Liminatus Pharma, Inc. Class A Common St to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Mahaka Media Tbk
JK:ABBA
|
0.036x |
|
Edgewater Wireless Systems Inc
V:YFI
|
0.163x |
|
Homebiogas Ltd
TA:HMGS
|
-0.172x |
|
Tapaco Public Company Limited
BK:TAPAC
|
0.056x |
|
DY6 Metals Ltd
AU:DY6
|
-0.086x |
|
HYPERCHARGE NETWORKS CORP
F:PB7
|
-0.296x |
|
Clever Group Corp
VN:ADG
|
N/A |
|
Scorpion Minerals Ltd
AU:SCN
|
-0.178x |
Annual Cash Flow Conversion Efficiency for Liminatus Pharma, Inc. Class A Common Stock (2021–2025)
The table below shows the annual cash flow conversion efficiency of Liminatus Pharma, Inc. Class A Common Stock from 2021 to 2025. View LIMN stock price and chart for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-9.81 Million | $-9.96 Million | 1.015x | +418.60% |
| 2024-12-31 | $-15.87 Million | $-3.11 Million | 0.196x | -37.43% |
| 2023-12-31 | $-10.69 Million | $-3.35 Million | 0.313x | +146.59% |
| 2022-12-31 | $1.29 Million | $-869.00K | -0.671x | -13974.82% |
| 2021-12-31 | $254.87 Million | $-1.22 Million | -0.005x | -- |
About Liminatus Pharma, Inc. Class A Common Stock
Liminatus Pharma, Inc., a pre-clinical stage biopharmaceutical company, engages in the development of cancer therapies in the United States. It develops IBA101, a humanized anti CD47 monoclonal antibody, which is in Phase I clinical trial for the treatment of advanced solid cancers, including non-small cell lung cancer. The company was founded in 2018 and is based in Cerritos, California.